Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Syndax Pharmaceuticals filings document regulatory disclosures for a commercial-stage cancer-therapy company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary financial information, product-revenue updates for Revuforj and Niktimvo, business presentations and material product events, including the FDA approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation and shareholder voting matters. Other material-event filings address governance changes, including director departures, and Regulation FD disclosures tied to investor presentations and operating updates.
Syndax Pharmaceuticals Head of R&D and CMO Nicholas A.J. Botwood reported an exercise-and-sell pattern in company stock. On June 11–12, he exercised stock options to acquire a total of 53,750 shares of common stock at $13.82 per share and sold 65,515 shares in open-market transactions around $18 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 60,885 common shares and has 16,537 vested and 289,413 unvested options to purchase additional shares.
The issuer submitted a Rule 144 notice for the proposed sale of 31,235 shares of common stock on 06/12/2026, listed on NASDAQ, associated with a stock option exercise and reported in cash. The filing also reports a prior sale of 34,280 shares on 06/11/2026 for $609,434.95.
Proposed sale of Common Stock by an affiliate was reported. The notice lists 11,565 shares referenced with an open market entry dated 05/16/2025, 200 shares from restricted stock vesting on 05/16/2025, and 22,515 shares tied to a stock option exercise on 06/11/2026.
Proposed sale of Common Stock by an affiliate was reported. The notice lists 11,565 shares referenced with an open market entry dated 05/16/2025, 200 shares from restricted stock vesting on 05/16/2025, and 22,515 shares tied to a stock option exercise on 06/11/2026.
Syndax Pharmaceuticals, Inc. issued $250.0 million of 2.25% Convertible Senior Notes due 2031 in a private placement to institutional investors. The notes were issued under an indenture with U.S. Bank Trust Company, National Association, as trustee.
Net proceeds were approximately $243.0 million after fees and expenses, which Syndax expects to use for general corporate purposes, including working capital, research and development, commercialization activities and business development. The notes and any conversion shares were sold relying on registration exemptions under Sections 4(a)(2) and 3(a)(9) of the Securities Act.
Based on an initial maximum conversion rate of 54.5256 shares per $1,000 principal amount, up to 13,631,400 shares of common stock may initially be issuable upon conversion, subject to customary anti-dilution adjustments.
Syndax Pharmaceuticals, Inc. reported results from its June 10, 2026 annual stockholder meeting, where all proposals passed. Stockholders approved the 2026 Equity Incentive Plan, which reserves 7,200,000 shares of common stock plus shares that may return from expired or forfeited awards under the prior 2015 plan.
They also approved a new 2026 Employee Stock Purchase Plan to replace the 2015 plan, with U.S. and non-U.S. components, both effective June 10, 2026. Stockholders elected all nominated directors, gave advisory approval to executive compensation, and ratified the company’s independent public accounting firm.
Syndax Pharmaceuticals has entered into privately negotiated subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, with expected net proceeds of about $243 million.
The notes are senior unsecured, pay 2.25% interest semiannually starting December 15, 2026, and mature on June 15, 2031, unless earlier converted, redeemed or repurchased. They are initially convertible at 40.3894 shares of common stock per $1,000 principal (an effective conversion price of about $24.76 per share), representing a roughly 35% premium to the June 3, 2026 share price. Under a higher maximum conversion rate of 54.5256 shares per $1,000, up to 13,631,400 shares may be issued.
Syndax may redeem the notes for cash on or after June 20, 2029 if its stock trades at least 130% of the conversion price for a specified period. Noteholders have conversion and repurchase rights upon certain trading, corporate or “fundamental change” events. The company plans to use proceeds for general corporate purposes, including working capital, research and development, commercialization and business development.
Syndax Pharmaceuticals has entered into privately negotiated subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, with expected net proceeds of about $243 million.
The notes are senior unsecured, pay 2.25% interest semiannually starting December 15, 2026, and mature on June 15, 2031, unless earlier converted, redeemed or repurchased. They are initially convertible at 40.3894 shares of common stock per $1,000 principal (an effective conversion price of about $24.76 per share), representing a roughly 35% premium to the June 3, 2026 share price. Under a higher maximum conversion rate of 54.5256 shares per $1,000, up to 13,631,400 shares may be issued.
Syndax may redeem the notes for cash on or after June 20, 2029 if its stock trades at least 130% of the conversion price for a specified period. Noteholders have conversion and repurchase rights upon certain trading, corporate or “fundamental change” events. The company plans to use proceeds for general corporate purposes, including working capital, research and development, commercialization and business development.
Syndax Pharmaceuticals Inc Chief Financial Officer Keith A. Goldan reported an open-market sale of 1,177 shares of common stock at $18.99 per share. According to the footnote, these shares were required to be sold to cover tax withholding obligations from the vesting of restricted stock units. Following the transaction, he held 139,252 shares directly, indicating this was a small, tax-related adjustment rather than a large discretionary sale.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger sold 6,847 shares of common stock in an open-market transaction. The shares were sold at an average price of $18.99 per share. According to the footnote, this sale was made to cover tax withholding obligations tied to vesting restricted stock units, and he continues to hold 484,843 shares afterward.